| Evaluation of meropenem‐ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance AA Agyeman, KE Rogers, JR Tait, PJ Bergen, CM Kirkpatrick, SC Wallis, ... Clinical Pharmacology & Therapeutics 109 (4), 1104-1115, 2021 | 18 | 2021 |
| Clinically relevant epithelial lining fluid concentrations of meropenem with ciprofloxacin provide synergistic killing and resistance suppression of hypermutable Pseudomonas … H Bilal, PJ Bergen, JR Tait, SC Wallis, AY Peleg, JA Roberts, A Oliver, ... Antimicrobial Agents and Chemotherapy 64 (7), 10.1128/aac. 00469-20, 2020 | 10 | 2020 |
| Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid … JR Tait, H Bilal, TH Kim, A Oh, AY Peleg, JD Boyce, A Oliver, PJ Bergen, ... Journal of Global Antimicrobial Resistance 26, 55-63, 2021 | 8 | 2021 |
| Simulated intravenous versus inhaled tobramycin with or without intravenous ceftazidime evaluated against hypermutable Pseudomonas aeruginosa via a dynamic biofilm model and … H Bilal, JR Tait, Y Lang, J Zhou, PJ Bergen, AY Peleg, JB Bulitta, A Oliver, ... Antimicrobial Agents and Chemotherapy 66 (3), e02203-21, 2022 | 6 | 2022 |
| Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the … JR Tait, H Bilal, KE Rogers, Y Lang, TH Kim, J Zhou, SC Wallis, JB Bulitta, ... Antibiotics 11 (1), 101, 2022 | 5 | 2022 |
| Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and … JR Tait, M Harper, S Cortés-Lara, KE Rogers, C López-Causapé, ... Antimicrobial Agents and Chemotherapy 67 (8), e00414-23, 2023 | 3 | 2023 |
| Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease RK Barr, BW Barber, JR Tait, CB Landersdorfer, S Salman, GC Musk, ... European Journal of Pharmaceutics and Biopharmaceutics 189, 240-250, 2023 | 2 | 2023 |
| Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling JR Tait, TC Barnett, KE Rogers, WL Lee, M Page-Sharp, L Manning, ... Journal of Antimicrobial Chemotherapy 77 (7), 1923-1930, 2022 | 1 | 2022 |
| Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based … SKJ Breen, M Harper, C López-Causapé, KE Rogers, JR Tait, ... International Journal of Antimicrobial Agents, 107161, 2024 | | 2024 |
| Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa JR Tait, D Anderson, RL Nation, DJ Creek, CB Landersdorfer Antimicrobial Agents and Chemotherapy, e01081-23, 2024 | | 2024 |
| Elucidating effects of single and multiple resistance mechanisms on bacterial response to meropenem by quantitative and systems pharmacology modeling and population genomics DT Fuhs, S Cortés-Lara, JR Tait, KE Rogers, C López-Causapé, WL Lee, ... bioRxiv, 2024.02. 17.579784, 2024 | | 2024 |
| Dynamic infection models, metabolomics and mechanism-based modelling to investigate pharmacodynamic challenges of Pseudomonas aeruginosa JR TAIT Monash University, 0 | | |
